Takeda will pay an initial $190m with a further $120m depending on the performance of its potential drugs targeting cancers that has begun making progress with the regulators.
Japan-based drugs company Takeda Pharmaceuticals has agreed to buy US-based oncology research group Intellikine from a syndicate including corporate venturing units for up to $310m.
Takeda will pay an initial $190m with a further $120m depending on the performance of its potential drugs targeting cancers that has begun making progress with the regulators.
Last month, US-based molecular drug developer Intellikine earned $4m in milestone payments from Infinity Pharmaceuticals. The payments were made after Intellikine’s IPI-145 inhibitor entered into Phase 1…
